Recruiting Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors NCT07288359 Conditions Advanced CCNE1-amplified Solid Tumors, Advanced HR+/HER2- Breast Cancer, Breast Diseases, +14 more Locations Tennessee Oncology PLLC — Nashville, Tennessee, United States START — San Antonio, Texas, United States Novartis Investigative Site — Olomouc, Czechia Novartis Investigative Site — Odense C, Denmark View all 15 locations View more locations Show fewer locations Loading locations... View Trial Details
Recruiting Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors NCT06726148 Conditions Advanced CCNE1-amplified Solid Tumors, Advanced HR+/HER2- Breast Cancer, Breast Diseases, +14 more Locations University of California LA — Los Angeles, California, United States Florida Cancer Specialists — Fort Myers, Florida, United States Dana Farber Cancer Institute — Boston, Massachusetts, United States WA Uni School Of Med — St Louis, Missouri, United States View all 33 locations View more locations Show fewer locations Loading locations... View Trial Details
